IQVIA Holdings
IQV
258.11
-1.87
-0.72%
IQVIA Holdings
US · IQV
#493 by market cap
Listed 1970
258.11
-1.87
-0.72%
Live - 5344 symbols - heartbeat 136s ago
· 2026-10-08 08:17
Pre-market
257.60
-0.20%
After-hours
258.11
0.00%
- Market cap
- 42.48B
- P/E (TTM)i
- 32.10
- P/Bi
- 6.88
- EPSi
- 7.84
- Div yieldi
- 0.00%
- 52W posi
- 84%
Reader sentiment
Are you bullish or bearish on IQV?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.15, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +5.87% YoY
Margins
- Gross margin
- 33.29%
- Operating margin
- 14.02%
- Net margin
- 8.34%
Key ratios & quality
- Enterprise valuei
- 56.07B
- PEG ratioi
- 4.21
- Altman Z-Scorei
- 2.15
PEG uses trailing P/E against the 3-year net income growth rate (7.62%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.41B | 11.09B | 11.36B | 13.87B | 14.41B | 14.98B | 15.41B | 16.31B |
| Gross profit | 3.67B | 3.79B | 3.86B | 4.64B | 5.03B | 5.24B | 5.38B | 5.43B |
| Selling & admin expenses | 1.72B | 1.73B | 1.79B | 1.96B | 2.07B | 2.05B | 1.99B | 2.00B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 809.00M | 852.00M | 783.00M | 1.41B | 1.83B | 2.06B | 2.27B | 2.29B |
| Pretax profit | 328.00M | 352.00M | 373.00M | 1.13B | 1.36B | 1.46B | 1.67B | 1.59B |
| Tax | 59.00M | 116.00M | 72.00M | 163.00M | 260.00M | 101.00M | 301.00M | 252.00M |
| Net profit | 284.00M | 227.00M | 308.00M | 971.00M | 1.09B | 1.36B | 1.37B | 1.36B |
| Basic EPS | 1 | 1 | 1 | 5 | 6 | 7 | 8 | 8 |
| Diluted EPS | 1.24 | 0.96 | 1.43 | 4.95 | 5.72 | 7.29 | 7.49 | 7.84 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 3.83B | 4.02B | 4.10B | 4.36B | 4.15B | 4.37B |
| Gross profit | 1.30B | 1.32B | 1.37B | 1.44B | 1.36B | 1.44B |
| Selling & admin expenses | 508.00M | 509.00M | 514.00M | 468.00M | 502.00M | 574.00M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 525.00M | 538.00M | 573.00M | 651.00M | 565.00M | 569.00M |
| Pretax profit | 323.00M | 323.00M | 408.00M | 537.00M | 328.00M | 301.00M |
| Tax | 61.00M | 56.00M | 76.00M | 59.00M | 59.00M | 60.00M |
| Net profit | 249.00M | 266.00M | 332.00M | 514.00M | 275.00M | 258.00M |
| Basic EPS | 1 | 2 | 2 | 3 | 2 | 2 |
| Diluted EPS | 1.40 | 1.54 | 1.93 | 2.99 | 1.61 | 1.53 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 3.87B | 4.13B | 5.09B | 4.76B | 4.98B | 5.60B | 5.83B | 6.25B |
| Cash & ST investments | 938.00M | 899.00M | 1.90B | 1.48B | 1.31B | 1.50B | 1.84B | 2.14B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 22.55B | 23.25B | 24.56B | 24.69B | 25.34B | 26.68B | 26.90B | 29.94B |
| Total current liabilities | 3.53B | 3.95B | 4.56B | 5.24B | 5.58B | 6.49B | 6.96B | 8.34B |
| Short-term debt | 100.00M | 100.00M | 149.00M | 91.00M | 152.00M | 718.00M | 1.15B | 1.84B |
| Long-term debt | 10.91B | 11.55B | 12.38B | 12.03B | 12.60B | 12.96B | 12.84B | 13.88B |
| Total liabilities | 15,595,000,000.00 | 16,988,000,000.00 | 18,284,000,000.00 | 18,647,000,000.00 | 19,572,000,000.00 | 20,569,000,000.00 | 20,832,000,000.00 | 23,314,000,000.00 |
| Total equity | 6.95B | 6.26B | 6.28B | 6.04B | 5.77B | 6.11B | 6.07B | 6.63B |
| Retained earnings | 807.00M | 998.00M | 1.28B | 2.24B | 3.33B | 4.69B | 6.07B | 7.43B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 5.91B | 6.35B | 5.98B | 6.25B | 6.22B | 6.23B |
| Cash & ST investments | 1.88B | 2.19B | 1.97B | 2.14B | 2.10B | 2.08B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 27.32B | 28.63B | 28.73B | 29.94B | 29.68B | 29.88B |
| Total current liabilities | 7.18B | 7.57B | 8.51B | 8.34B | 8.33B | 8.82B |
| Short-term debt | 1.22B | 1.31B | 2.16B | 1.84B | 1.84B | 2.29B |
| Long-term debt | 13.11B | 14.18B | 12.79B | 13.88B | 13.99B | 13.71B |
| Total liabilities | 21,337,000,000.00 | 22,846,000,000.00 | 22,439,000,000.00 | 23,314,000,000.00 | 23,326,000,000.00 | 23,580,000,000.00 |
| Total equity | 5.99B | 5.79B | 6.29B | 6.63B | 6.35B | 6.30B |
| Retained earnings | 6.31B | 6.58B | 6.91B | 7.43B | 7.70B | 7.96B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.25B | 1.42B | 1.96B | 2.94B | 2.26B | 2.15B | 2.72B | 2.65B |
| Depreciation & amortization | 1.14B | 1.20B | 1.29B | 1.26B | 1.13B | 1.13B | 1.11B | 1.14B |
| Free cash flow | 795.00M | 835.00M | 1.34B | 2.30B | 1.59B | 1.50B | 2.11B | 2.05B |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -1.41B | -949.00M | -447.00M | -406.00M | -1.17B | -992.00M | -1.35B | -1.24B |
| Ending cash balance | 891.00M | 837.00M | 1.81B | 1.37B | 1.22B | 1.38B | 1.70B | 1.98B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 568.00M | 443.00M | 908.00M | 735.00M | 618.00M | 558.00M |
| Depreciation & amortization | 265.00M | 276.00M | 286.00M | 317.00M | 288.00M | 292.00M |
| Free cash flow | 426.00M | 292.00M | 772.00M | 561.00M | 491.00M | 360.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -375.00M | -657.00M | 0 | -212.00M | -552.00M | -398.00M |
| Ending cash balance | 1.74B | 2.04B | 1.81B | 1.98B | 1.95B | 1.91B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 3.49 | 3.00 | 4.65 | 16.04 | 18.48 | 22.87 | 22.55 | 21.64 |
| ROA %i | 1.14 | 0.83 | 1.17 | 3.92 | 4.36 | 5.22 | 5.13 | 4.79 |
| ROIC %i | 3.28 | 2.71 | 3.30 | 6.86 | 7.61 | 10.06 | 9.37 | 9.07 |
| 5-year avg ROE %i | -- | -- | 5.66 | 8.52 | 9.14 | 13.01 | 16.92 | 20.32 |
| EBIT margin %i | 7.13 | 7.21 | 6.95 | 10.83 | 12.35 | 14.22 | 15.18 | 14.22 |
| FCF / sales %i | 7.64 | 7.53 | 11.82 | 16.59 | 11.01 | 10.01 | 13.72 | 12.58 |
| Current ratioi | 1.10 | 1.05 | 1.12 | 0.91 | 0.89 | 0.86 | 0.84 | 0.75 |
| Quick ratioi | 0.96 | 0.90 | 0.96 | 0.78 | 0.77 | 0.76 | 0.73 | 0.67 |
| Debt / assetsi | 48.81 | 51.79 | 52.53 | 50.38 | 51.35 | 52.08 | 52.63 | 53.26 |
| LT debt / equityi | 162.45 | 198.92 | 212.55 | 204.35 | 223.05 | 215.61 | 214.46 | 216.96 |
| Interest coveragei | 1.79 | 1.79 | 1.90 | 4.01 | 4.28 | 3.17 | 3.49 | 3.18 |
| Revenue CAGR (3Y) %i | 21.98 | 17.61 | 5.40 | 10.04 | 9.13 | 9.67 | 3.55 | 4.21 |
| Net income CAGR (3Y) %i | -12.53 | 38.43 | -39.77 | 55.08 | 78.76 | 69.47 | 12.43 | 7.62 |
| FCF CAGR (3Y) %i | 25.94 | 6.26 | 30.74 | 42.53 | 23.84 | 3.75 | -2.80 | 8.95 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 21.65 | 19.80 | 19.55 | 21.64 | 22.71 | 23.01 |
| ROA %i | 4.95 | 4.50 | 4.59 | 4.79 | 4.86 | 4.70 |
| ROIC %i | 9.06 | 8.44 | 8.66 | 9.07 | 9.28 | 9.06 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 14.98 | 14.18 | 14.49 | 14.22 | 14.14 | 13.81 |
| FCF / sales %i | 13.96 | 12.80 | 13.90 | 12.58 | 12.72 | 12.86 |
| Current ratioi | 0.82 | 0.84 | 0.70 | 0.75 | 0.75 | 0.71 |
| Quick ratioi | 0.72 | 0.74 | 0.62 | 0.67 | 0.66 | 0.62 |
| Debt / assetsi | 53.10 | 54.83 | 52.88 | 53.26 | 54.14 | 54.35 |
| LT debt / equityi | 222.27 | 249.00 | 211.46 | 216.96 | 228.60 | 226.01 |
| Interest coveragei | 3.47 | 3.24 | 3.26 | 3.18 | 3.11 | 3.04 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Research & Development Solutions is the largest reported line at 58.95% of revenue, across 2 reported segments.
- Commercial Solutions follows at 41.05%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Research & Development Solutions58.95%
Commercial Solutions41.05%
Quote time 2026-10-08 08:17:53 · For reference only, not investment advice and not tailored to your situation.